Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma

B-Cell Lymphoma Clinical Trial

— PCYC-04753  

Official title:

Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00849654
• Other study ID #: PCYC-04753
• Status: Completed
• Phase: Phase 1
• First received: February 20, 2009
• Last updated: May 21, 2013
• Start date: February 2009
• Est. completion date: July 2012

Study information

• Verified date: May 2013
• Source: Pharmacyclics
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to establish the safety and optimal dose of orally administered PCI-32765 in patients with recurrent B cell lymphoma.

Other known NCT identifiers

• NCT01177878

Recruitment information / eligibility

• Status: Completed
• Enrollment: 66
• Est. completion date: July 2012
• Est. primary completion date: July 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Women and men = 18 years of age. There is no experience with this drug in a pediatric population.

• Body weight = 40 kg.

• Recurrent surface immunoglobulin positive B cell non-Hodgkin's lymphoma (NHL) according to WHO classification, including small lymphocytic lymphoma/ chronic lymphocytic leukemia (SLL/CLL) lymphoplasmacytic lymphoma, including Waldenström's Macroglobulinemia (WM), and pre-identified DLBCL ABC subtype oFor the DLBCL-ABC cohort, documented, activated B-cell subtype by either immunohistochemistry or tissue microarray analysis.

• Measurable disease (for NHL, bidimensional disease = 2 cm diameter in at least one dimension, for CLL = 5000 leukemia cells/mm3, for WM presence of immunoglobulin M paraprotein with a minimum IgM level = 1000 mg/dL and infiltration of bone marrow by lymphoplasmacytic cells), and pre-identified DLBCL ABC subtype by immunohistochemistry (IHC).

• Have failed = 1 previous treatment for lymphoma and no standard therapy is available. Patients with diffuse large B cell lymphoma must have failed, refused or be ineligible for autologous stem cell transplant.

• ECOG performance status of = 1.

• Ability to swallow oral capsules without difficulty.

• Willing and able to sign a written informed consent.

Exclusion Criteria:

• More than four prior systemic therapies (not counting maintenance rituximab), except for CLL patients. Salvage therapy/conditioning regimen leading up to autologous bone marrow transplantation is considered to be one regimen (This inclusion criterion does not apply to the DLBCL-ABC cohort).

• Prior allogeneic bone marrow transplant.

• Immunotherapy, chemotherapy, radiotherapy or experimental therapy within 4 weeks before first day of study drug dosing.

• Major surgery within 4 weeks before first day of study drug dosing.

• CNS involvement by lymphoma.

• Active opportunistic infection or treatment for opportunistic infection within 4 weeks before first day of study drug dosing.

• History of malabsorption.

• Laboratory abnormalities:

• Creatinine > 1.5 × institutional upper limit of normal (ULN)

• Total bilirubin > 1.5 x institutional ULN (unless elevated from documented Gilbert's syndrome)

• AST or ALT > 2.5 × institutional ULN

• Platelet count < 75,000/µL (unless patients have CLL and bone-marrow involvement, provided they are not transfusion-dependent)

• Absolute neutrophil count (ANC) < 1500/µL (unless patients have CLL and bone-marrow involvement)

• Hgb < 8.0 g/dL

• Uncontrolled illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III or IV heart failure), unstable angina pectoris, cardiac arrhythmia, and psychiatric illness that would limit compliance with study requirements.

• Risk factors for, or use of medications known to prolong QTc interval or that may be associated with Torsades de Pointes within 7 days of treatment start.

• QTc prolongation (defined as a QTc > 450 msecs) or other significant ECG abnormalities including 2nd degree AV block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50 beats/min). If the screening ECG has a QTc > 450 msecs, the ECG can be submitted for a centralized, cardiologic evaluation.

• History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty and/or stenting within the past 6 months.

• Known HIV infection.

• Hepatitis B sAg or Hepatitis C positive.

• Other medical or psychiatric illness or organ dysfunction which, in the opinion of the investigator, would either compromise the patient's safety or interfere with the evaluation of the safety of the study agent.

• Pregnant or lactating women (female patients of child-bearing potential must have a negative serum pregnancy test within 14 days of first day of drug dosing, or, if positive, a pregnancy ruled out by ultrasound).

• Women of child-bearing potential or sexually active men, unwilling to use adequate contraceptive protection during the course of the study.

• History of prior cancer < 2 years ago, except for basal cell or squamous cell carcinoma of the skin, cervical cancer in situ or other in situ carcinomas.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• B-Cell Leukemia
• B-Cell Lymphoma
• Leukemia, B-Cell
• Leukemia, Lymphocytic, Chronic, B-Cell
• Lymphoma
• Lymphoma, B-Cell

Intervention

Drug:
• PCI-32765
In the dose-escalation cohorts, PCI-32765 will be administered in 1.25, 2.5, 5.0, 8.3, 12.5, and 17.5 mg/kg/d dose orally once per day for 28 days followed by a 7-day rest period to determine the MTD. If MTD is not reached, dosing levels may be increased beyond 17.5mg/kg/d by 33% increments. In the continuous dosing cohorts, PCI-32765 will be administered in 8.3 mg/kg/day and 560 mg/day (fixed dose) dose orally once per day for 35 days.

Locations

Country	Name	City	State
United States	National Cancer Institute	Bethesda	Maryland
United States	University of Vermont College of Medicine	Burlington	Vermont
United States	University of Chicago	Chicago	Illinois
United States	Willamette Valley Cancer Institute/Research Ctr	Eugene	Oregon
United States	University of Texas, MD Anderson	Houston	Texas
United States	New York Prebyterian Hospital Cornell Medical Center	New York	New York
United States	Stanford University School of Medicine	Palo Alto	California
United States	Northwest Cancer Specialists, Vancouver Cancer Center	Vancouver	Washington
United States	Yakima Valley Memorial Hospital/North Star Lodge Cancer Ctr	Yakima	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Pharmacyclics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose limiting toxicity assessment for each patient.		At the end of the first 35 day cycle	Yes
Primary	Adverse events		30 days after last dose of study drug	Yes
Primary	Pharmacokinetic/ Pharmacodynamic assessments		during Cycle 1	No
Secondary	Tumor response		at the end of Cycles 2, 4, and 6 unitl progression	No

External Links

•   Link